more

Moderna (MRNA)

(Delayed Data from NSDQ)

$68.28 USD

-1.40 (-2.01%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine

by Ritujay Ghosh Published on July 07,2020

The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.

Moderna Shares Lose Momentum After Meteoric Rise: Here's Why

by Zacks Equity Research Published on July 06,2020

The encouraging progress with mRNA-based coronavirus vaccine drives meteoric rise in Moderna's (MRNA) shares. However, a rumored concern leads to correction.

biotechs

Company News for Jul 6, 2020

by Zacks Equity Research Published on July 06,2020

Companies In The News Are: TSLA, ALK, MRNA, BA.

Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen

by Sweta Jaiswal, FRM Published on July 03,2020

As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.

Pfizer Reports Encouarging Data From Coronavirus Program

by Zacks Equity Research Published on July 02,2020

Pfizer (PFE) announces promising preliminary data on a vaccine candidate from its early-stage coronavirus program under which it is developing four mRNA-based vaccine candidates.

pharmaceuticals

Are Options Traders Betting on a Big Move in Moderna (MRNA) Stock?

by Zacks Equity Research Published on July 02,2020

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

MRNANegative Net Change

medical

FDA Issues Guidance for Coronavirus Vaccine Developers

by Kinjel Shah Published on July 01,2020

Around a dozen companies are developing a vaccine for the deadly coronavirus disease.

pharmaceuticals

Investing Strategies for 2H Amid Coronavirus Resurgence

by Sanghamitra Saha Published on June 30,2020

Investors should prepare well before investing in 2H as many market watchers are suspecting rising volatility ahead.

Vaxart's Oral Coronavirus Vaccine Candidate Gets Chosen by OWS

by Zacks Equity Research Published on June 29,2020

Vaxart's (VXRT) oral COVID-19 vaccine candidate is picked for a non-human primate challenge study as part of the Operation Warp Speed initiative to rapidly develop a vaccine against SARS-CoV-2.

medical

Top Leveraged ETFs of Last Week

by Sanghamitra Saha Published on June 29,2020

Leveraged gold miners and treasury ETFs gained last week despite a market crash.

etfs

Moderna (MRNA) Stock Moves -1.16%: What You Should Know

by Zacks Equity Research Published on June 26,2020

In the latest trading session, Moderna (MRNA) closed at $61.28, marking a -1.16% move from the previous day.

MRNANegative Net Change

Moderna Collaborates With Catalent for Coronavirus Vaccine

by Zacks Equity Research Published on June 26,2020

Moderna (MRNA) teams up with Catalent for large-scale, commercial fill-finish manufacturing of the former's mRNA-based COVID-19 vaccine candidate.

biotechs

3 Stocks to Buy as Companies Speed Up Vaccine Production

by Ritujay Ghosh Published on June 26,2020

Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.

Bull of the Day: Quidel (QDEL)

by Kevin Cook Published on June 26,2020

Multiple FDA approvals for new 15-minute COVID-19 antigen tests have estimates and shares rising sharply

Invest in the Future With Megatrend ETFs

by Neena Mishra Published on June 25,2020

These ETFs invest in fast growing areas like robotics and AI, genomics and cybersecurity.

etf
etfs

Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on June 25,2020

Is (MRNA) Outperforming Other Medical Stocks This Year?

MRNANegative Net Change

New GERM ETF Launched to Tap the Growing Biotech Sector

by Sweta Killa Published on June 23,2020

GERM invests in the hottest emerging biotechnology trends.

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research Published on June 17,2020

Moderna (MRNA) closed at $63.31 in the latest trading session, marking a -1.6% move from the prior day.

MRNANegative Net Change

Novavax (NVAX) Up More Than 1200% Year to Date: Here's Why

by Zacks Equity Research Published on June 17,2020

Novavax's (NVAX) coronavirus vaccine candidate NVX-CoV2373 enters clinical studies. The company also plans to file a BLA on its influenza vaccine candidate, NanoFlu.